Antonio J Carcas SansuÃ;n

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8054032/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet, The, 2021, 398, 121-130.	13.7	316
2	A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe. Journal of Clinical Medicine, 2020, 9, 1733.	2.4	218
3	Lopinavir/Ritonavir as Single-Drug Therapy for Maintenance of HIV-1 Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 280-287.	2.1	164
4	Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respiratory Medicine,the, 2015, 3, 554-562.	10.7	113
5	Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clinical Pharmacology and Therapeutics, 1999, 65, 245-250.	4.7	71
6	Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification System. British Journal of Clinical Pharmacology, 2010, 70, 694-702.	2.4	70
7	Trough Tacrolimus Concentrations in the First Week After Kidney Transplantation Are Related to Acute Rejection. Therapeutic Drug Monitoring, 2009, 31, 436-442.	2.0	67
8	A Pharmacovigilance Program From Laboratory Signals for the Detection and Reporting of Serious Adverse Drug Reactions in Hospitalized Patients. Clinical Pharmacology and Therapeutics, 2010, 87, 74-86.	4.7	67
9	Overuse of PPIs in Patients at Admission, During Hospitalisation, and at Discharge in a Terciary Spanish Hospital. Current Clinical Pharmacology, 2010, 5, 288-297.	0.6	67
10	Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. Lancet Infectious Diseases, The, 2021, 21, 783-792.	9.1	62
11	Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacological Research, 2017, 115, 168-178.	7.1	61
12	Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax, 2021, 76, 920-929.	5.6	60
13	Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. Journal of Clinical Pharmacy and Therapeutics, 2006, 31, 393-396.	1.5	58
14	An Acenocoumarol Dosing Algorithm Using Clinical and Pharmacogenetic Data in Spanish Patients with Thromboembolic Disease. PLoS ONE, 2012, 7, e41360.	2.5	52
15	Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study. Clinical Pharmacology and Therapeutics, 2018, 104, 317-325.	4.7	46
16	Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. European Journal of Pharmacology, 2010, 626, 200-204.	3.5	43
17	Inhaled Methoxyflurane Provides Greater Analgesia and Faster Onset of Action Versus Standard Analgesia in Patients With Trauma Pain: InMEDIATE: A Randomized Controlled Trial in Emergency Departments. Annals of Emergency Medicine, 2020, 75, 315-328.	0.6	38
18	A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 466.	1.6	38

#	Article	IF	CITATIONS
19	Clinical Implementation of Pharmacogenetic Testing in a Hospital of the Spanish National Health System: Strategy and Experience Over 3 Years. Clinical and Translational Science, 2018, 11, 189-199.	3.1	37
20	Appropriate use of red blood cell transfusion in emergency departments: a study in five emergency departments. Blood Transfusion, 2017, 15, 199-206.	0.4	36
21	PHASE I PHARMACOKINETIC STUDY OF A SINGLE INTRAVESICAL INSTILLATION OF GEMCITABINE ADMINISTERED IMMEDIATELY AFTER TRANSURETHRAL RESECTION PLUS MULTIPLE RANDOM BIOPSIES IN PATIENTS WITH SUPERFICIAL BLADDER CANCER. Journal of Urology, 2004, 172, 485-488.	0.4	34
22	Activated charcoal increases digoxin elimination in patients. International Journal of Cardiology, 1995, 48, 27-30.	1.7	31
23	Digoxin Level and Clinical Manifestations as Determinants in the Diagnosis of Digoxin Toxicity. Therapeutic Drug Monitoring, 2000, 22, 163-168.	2.0	29
24	Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. Nature Biotechnology, 2022, 40, 1680-1689.	17.5	29
25	Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. Pharmacological Research, 2009, 59, 393-398.	7.1	27
26	DRESS-syndrome on sulfasalazine and naproxen treatment for juvenile idiopathic arthritis and reactivation of human herpevirus 6 in an 11-year-old caucasian boy. Journal of Clinical Pharmacy and Therapeutics, 2010, 35, 365-370.	1.5	27
27	Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. British Journal of Clinical Pharmacology, 2017, 83, 400-415.	2.4	27
28	Hypercalcemia due to an interaction of all-trans retinoic acid (ATRA) and itraconazole therapy for acute promyelocytic leukemia successfully treated with zoledronic acid. European Journal of Clinical Pharmacology, 2008, 64, 1031-1032.	1.9	26
29	Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation. Journal of Antimicrobial Chemotherapy, 2004, 54, 1148-1151.	3.0	23
30	Pharmacogenetics of quetiapine in healthy volunteers. International Clinical Psychopharmacology, 2015, 30, 82-88.	1.7	23
31	Effect of <i><scp>CYP</scp>4F2</i> , <i><scp>VKORC</scp>1</i> , and <i><scp>CYP</scp>2C9</i> in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	4.7	23
32	Severe Hyponatremia Is Often Drug Induced: 10‥ear Results of a Prospective Pharmacovigilance Program. Clinical Pharmacology and Therapeutics, 2019, 106, 1362-1379.	4.7	21
33	Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits. European Journal of Clinical Pharmacology, 2003, 59, 169-175.	1.9	20
34	Sublingual administration of tacrolimus in a renal transplant patient. Journal of Clinical Pharmacy and Therapeutics, 2008, 33, 87-89.	1.5	20
35	Drug-induced life-threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals. European Journal of Clinical Pharmacology, 2013, 69, 97-110.	1.9	18
36	Incidence of Suspected Serious Adverse Drug Reactions in Corona Virus Disease-19 Patients Detected by a Pharmacovigilance Program by Laboratory Signals in a Tertiary Hospital in Spain: Cautionary Data. Frontiers in Pharmacology, 2020, 11, 602841.	3.5	18

#	Article	IF	CITATIONS
37	Hepatotoxicity induced by acute and chronic paracetamol overdose in adults. Where do we stand?. Regulatory Toxicology and Pharmacology, 2015, 72, 370-378.	2.7	17
38	A New Pharmacogenetic Algorithm to Predict the Most Appropriate Dosage of Acenocoumarol for Stable Anticoagulation in a Mixed Spanish Population. PLoS ONE, 2016, 11, e0150456.	2.5	17
39	Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population. International Journal of Antimicrobial Agents, 2019, 54, 463-470.	2.5	17
40	Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. Trials, 2012, 13, 239.	1.6	15
41	Outcomes and Costs of Poisoned Patients Admitted to an Adult Emergency Department of a Spanish Tertiary Hospital: Evaluation through a Toxicovigilance Program. PLoS ONE, 2016, 11, e0152876.	2.5	14
42	Conversion from Prograf to Advagraf in stable paediatric renal transplant patients and 1-year follow-up. Pediatric Nephrology, 2014, 29, 117-123.	1.7	13
43	Nimodipine Transfer into Human Breast Milk and Cerebrospinal Fluid. Annals of Pharmacotherapy, 1996, 30, 148-150.	1.9	12
44	Bioequivalence of allopurinol and its metabolite oxipurinol in two tablet formulations. Journal of Clinical Pharmacy and Therapeutics, 2001, 26, 113-119.	1.5	12
45	Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6. Pharmacogenomics Journal, 2013, 13, 452-455.	2.0	12
46	Limited sampling strategies for tacrolimus exposure (AUC ₀₋₂₄) prediction after Prograf [®] and Advagraf [®] administration in children and adolescents with liver or kidney transplants. Transplant International, 2014, 27, 939-948.	1.6	12
47	Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant. Pharmacogenomics Journal, 2018, 18, 180-186.	2.0	12
48	Predictive engines based on pharmacokinetics modelling for tacrolimus personalized dosage in paediatric renal transplant patients. Scientific Reports, 2020, 10, 7542.	3.3	12
49	Conversion from Prograf to Advagraf in Adolescents with stable liver transplants: Comparative pharmacokinetics and 1-year follow-up. Liver Transplantation, 2013, 19, 1151-1158.	2.4	11
50	Evaluation of Sex Differences in the Pharmacokinetics of Ranitidine in Humans. Journal of Clinical Pharmacology, 1996, 36, 748-751.	2.0	10
51	Cefminox versus Metronidazole plus Gentamicin in Intra-abdominal Infections: A Prospective Randomized Controlled Clinical Trial. Infection, 2000, 28, 318-322.	4.7	10
52	Antibacterial Properties of Gemifloxacin and Trovafloxacin in Urine Ex Vivo: Phase I Study. Antimicrobial Agents and Chemotherapy, 2001, 45, 1876-1878.	3.2	10
53	Vancomycin-Induced Acute Kidney Injury Detected by a Prospective Pharmacovigilance Program From Laboratory Signals. Therapeutic Drug Monitoring, 2013, 35, 360-366.	2.0	10
54	Effects of aripiprazole on pupillometric parameters related to pharmacokinetics and pharmacogenetics after single oral administration to healthy subjects. Journal of Psychopharmacology, 2018, 32, 1212-1222.	4.0	10

#	Article	IF	CITATIONS
55	Urinary Concentrations and Bactericidal Activity Against Amoxicillin-Nonsusceptible Strains of Escherichia coli with Single-Dose, Oral, Sustained-Release Amoxicillin/Clavulanic Acid: A Phasel, Open-Label, Noncomparative Clinical Trial in Healthy Volunteers. Clinical Therapeutics, 2005, 27, 1043-1049.	2.5	9
56	The importance of sample size, log-mean ratios, and intrasubject variability in the acceptance criteria of 108 bioequivalence studies. European Journal of Clinical Pharmacology, 2008, 64, 783-793.	1.9	9
57	CYP2C9 polymorphism in five autochthonous population of the same geographic area (Spanish) Tj ETQq1 1 0.78	84314 rgB 7.1	T /Qverlock
58	Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. Pharmacogenomics, 2013, 14, 1203-1214.	1.3	9
59	Public preferences on written informed consent for lowâ€risk pragmatic clinical trials in Spain. British Journal of Clinical Pharmacology, 2017, 83, 1921-1931.	2.4	9
60	Cefminox: correlation between in-vitro susceptibility and pharmacokinetics and serum bactericidal activity in healthy volunteers. Journal of Antimicrobial Chemotherapy, 1994, 33, 91-101.	3.0	8
61	Nonâ€Chemotherapyâ€Induced Agranulocytosis Detected by a Prospective Pharmacovigilance Program in a Tertiary Hospital. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 399-408.	2.5	8
62	Nonchemotherapy drug-induced agranulocytosis in children detected by a prospective pharmacovigilance program. Pediatric Hematology and Oncology, 2016, 33, 441-456.	0.8	8
63	A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis. Pharmaceuticals, 2022, 15, 78.	3.8	8
64	Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol. BMJ Open, 2020, 10, e037443.	1.9	8
65	Measurement of tobramycin in broncboalveolar lavage fluid by a modified fluorescence polarization immunoassay. Journal of Antimicrobial Chemotherapy, 1995, 36, 1111-1113.	3.0	7
66	Use of antifungal agents in pediatric and adult high-risk areas. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 337-347.	2.9	7
67	Hepatotoxicity induced by acute and chronic paracetamol overdose in children: Where do we stand?. World Journal of Pediatrics, 2017, 13, 76-83.	1.8	7
68	Patients' beliefs regarding informed consent for low-risk pragmatic trials. BMC Medical Research Methodology, 2017, 17, 145.	3.1	7
69	Melatonin in the Prophylaxis of SARS-CoV-2 Infection in Healthcare Workers (MeCOVID): A Randomised Clinical Trial. Journal of Clinical Medicine, 2022, 11, 1139.	2.4	7
70	Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroid X receptor and constitutive androstane receptor in 207 healthy Spanish volunteers. Clinical Chemistry and Laboratory Medicine, 2010, 48, 635-9.	2.3	6
71	A multiplex assay to detect variations in the CYP2C9, VKORC1, CYP4F2 and APOE genes involved in acenocoumarol metabolism. Clinical Biochemistry, 2013, 46, 167-169.	1.9	6
72	Does Acetaminophen Interfere in the Antibiotic Treatment of Acute Otitis Media Caused by a Penicillin-Resistant Pneumococcus Strain? A Gerbil Model. Pediatric Research, 2003, 54, 913-918.	2.3	5

#	Article	IF	CITATIONS
73	Pulmonary Damage and Bacterial Load in Assessment of the Efficacy of Simulated Human Treatment-Like Amoxicillin (2,000 Milligrams) Therapy of Experimental Pneumococcal Pneumonia Caused by Strains for Which Amoxicillin MICs Differ. Antimicrobial Agents and Chemotherapy, 2005, 49, 996-1001.	3.2	5
74	In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication. Journal of Medical Virology, 2009, 81, 211-216.	5.0	5
75	Who is willing to participate in low-risk pragmatic clinical trials without consent?. European Journal of Clinical Pharmacology, 2017, 73, 1557-1563.	1.9	5
76	Pharmacometabolomics applied to zonisamide pharmacokinetic parameter prediction. Metabolomics, 2018, 14, 70.	3.0	5
77	Strategy to effectively and efficiently implementÂvoriconazole pharmacogenetics in clinical practice. Pharmacogenomics, 2020, 21, 647-649.	1.3	5
78	Comparative Bioavailability of Two Oral 875/125mg Sachet Formulations of Amoxicillin/Clavulanic Acid in Healthy Volunteers. Clinical Drug Investigation, 1999, 18, 217-224.	2.2	4
79	Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers. Journal of Antimicrobial Chemotherapy, 2005, 55, 742-747.	3.0	4
80	Evaluating the optimal time for amikacin administration with respect to haemodialysis using an in vitro pharmacodynamic simulation against epidemic nosocomial OXA-48 producing Klebsiella pneumoniae ST405 strains. Journal of Global Antimicrobial Resistance, 2019, 19, 241-251.	2.2	4
81	Influence of Genetic Polymorphisms on the Response to Tramadol, Ibuprofen, and the Combination in Patients With Moderate to Severe Pain After Dental Surgery. Clinical Therapeutics, 2021, 43, e86-e102.	2.5	4
82	Acenocoumarol Pharmacogenetic Dosing Algorithm versus Usual Care in Patients with Venous Thromboembolism: A Randomised Clinical Trial. Journal of Clinical Medicine, 2021, 10, 2949.	2.4	4
83	Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation. Frontiers in Pharmacology, 2021, 12, 717932.	3.5	4
84	A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2005, 55, 453-460.	2.3	3
85	High dose favipiravir: first experience in a patient with Ebola. Clinical Therapeutics, 2015, 37, e15-e16.	2.5	3
86	Comparison of Lormetazepam Solution and Capsules in Healthy Volunteers. Clinical Drug Investigation, 2002, 22, 859-866.	2.2	2
87	A Preliminary Model to Avoid the Overestimation of Sample Size in Bioequivalence Studies. Drug Research, 2013, 63, 98-103.	1.7	2
88	Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible Aspergillus fumigatus: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms. International Journal of Antimicrobial Agents, 2016, 47, 410-411.	2.5	2
89	Health Care Workers' Reasons for Choosing Between Two Different COVID-19 Prophylaxis Trials in an Acute Pandemic Context: Single-Center Questionnaire Study. Journal of Medical Internet Research, 2021, 23, e23441.	4.3	2
90	Implementación de la farmacogenética en la práctica clÃnica: hacia las estrategias de genotipado anticipado. IBJ Clinical Pharmacology, 2016, 1, .	0.0	2

Antonio J Carcas SansuÃin

#	Article	IF	CITATIONS
91	Average bioequivalence of two oral formulations of ticlopidine in healthy volunteers. Current Therapeutic Research, 2000, 61, 523-533.	1.2	1
92	Electronic medical record in clinical trials of effectiveness of drugs integrated in clinical practice. Medicina ClÂnica (English Edition), 2015, 145, 452-457.	0.2	1
93	Influence of two variants of CYP450 oxidoreductase on the stable dose of acenocoumarol in a Spanish population. Pharmacogenomics, 2017, 18, 797-805.	1.3	1
94	Comparative effectiveness medicines research cannot assess efficacy. Journal of Clinical Epidemiology, 2017, 92, 129.	5.0	1
95	Efficient diagnosis and treatment of acute paracetamol poisoning: cost-effectiveness analysis of approaches based on a hospital toxicovigilance program. Emergencias, 2018, 30, 169-176.	0.6	1
96	Uam Course on Good Clinical Practice (Gcps) for Investigators: A 3 Years Experience. Clinical Therapeutics, 2015, 37, e129.	2.5	0
97	A Pharmacovigilance Program from Laboratory Signals In Hospitalizaed Patients: Results Of 2014. Clinical Therapeutics, 2015, 37, e137.	2.5	0
98	Sat-Hulp Toxicovigilance program: Results of 30 Months. Clinical Therapeutics, 2015, 37, e128.	2.5	0
99	Pharmacogenetic Implementation In The Routine Clinical Practice: Design of A Multicenter Pilot Clinical Trial. Clinical Therapeutics, 2015, 37, e129-e130.	2.5	0
100	Cytochrome P450 Oxidoreductase Contribution On An Acenocoumarol Dosing Algorithm. Clinical Therapeutics, 2015, 37, e131.	2.5	0
101	Screening and Recruitment Procedures of Healthy Volunteers In A Phase I Clinical Trial Unit: Experience In 64 Bioequivalence Studies. Clinical Therapeutics, 2015, 37, e129.	2.5	0
102	Limited sampling strategies for once daily tacrolimus exposure monitoring. European Journal of Clinical Pharmacology, 2016, 72, 773-774.	1.9	0
103	The need to implement non-industry COVID-19 clinical trials in non-high-income countries. Journal of Global Health, 2020, 10, 010351.	2.7	0
104	In reply:. Annals of Emergency Medicine, 2020, 75, 551-552.	0.6	0